Research programme: haemophilia therapeutics - Shire/Xenetic Biosciences

Drug Profile

Research programme: haemophilia therapeutics - Shire/Xenetic Biosciences

Alternative Names: Factor VIII - Xenetic Biosciences; LA rfVIII PSA; Long-acting blood clotting factors - Shire/Xenetic Biosciences; Polysialylated blood coagulation factors - Shire/Xenetic Biosciences

Latest Information Update: 28 Nov 2016

Price : $50

At a glance

  • Originator Baxter International; Lipoxen Technologies
  • Developer Shire; Xenetic Biosciences
  • Class Blood coagulation factors; Recombinant proteins
  • Mechanism of Action Blood coagulation factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Haemophilia

Most Recent Events

  • 23 Nov 2016 Xenetic Biosciences and Shire agree to co-promote and co-develop drugs for treatment of Blood and Bleeding disorders
  • 03 Jun 2016 Baxalta has been acquired and merged into Shire
  • 30 Jun 2013 Preclinical development is ongoing in US and EU
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top